Researchers have identified YAP and TAZ as crucial regulators of macrophage-mediated pulmonary inflammation and fibrosis, ...

A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in ...

A discovery at Duke-NUS Medical School offers new hope in the battle against pulmonary fibrosis, a debilitating lung ...

Pulmonary hypertension, despite advances in treatment, still has a poor prognosis, which is often associated with right heart failure, and for which pulmonary arterial hypertension (PAH) is a severe ...

The median length of survival for individuals with ILD who completed pulmonary rehabilitation was 6.1 years vs 4.7 years in the control group. Pulmonary rehabilitation (PR) may improve survival at 5 ...

The immune protein STAT6 may be a driver of pulmonary hypertension in people with obstructive sleep apnea, a study in mice ...

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

The full lineup of late-breaking clinical science to be presented at THT 2025: Technology and Heart Failure Therapeutics is now available online. Organized by the Cardiovascular Research Foundation® ...

COVID-19 may weaken arterial stability – The study found that lesions in previously infected individuals had a higher prevalence of "positive remodeling," a sign of unstable plaque that is more ...

Suggested approach: A chronic history, markedly elevated systolic pulmonary arterial pressures, RV and bronchial artery hypertrophy, thrombus calcification, webs and a mosaic perfusion pattern should ...